Capricor Therapeutics Inc. announced the execution of an Exclusive License Agreement with Cedars-Sinai Medical Center for intellectual property (IP) related to the development of exosomes.
Cardiovascular Systems Inc. (CSI) announced that the first patient has been enrolled in its Coronary Orbital Atherectomy System Trial (COAST) trial.

June 11, 2014 — GE Healthcare introduced its Discovery IQ PET/CT (positron emission tomography/computed tomography) system at the 2014 annual meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) in St. Louis. The system enables both high image quality and intelligent quantitation. It is pending 510(k) clearance from the U.S. Food and Drug Administration (FDA) and not available for sale in the United States.
SPONSORED CONTENT — Studycast is a comprehensive imaging workflow system that allows healthcare professionals to work ...
Medtronic Inc. announced five-year follow-up data demonstrating the safety and performance of the Medtronic 3f Enable Aortic Bioprosthesis — the world's first commercially available sutureless tissue heart valve.
Heart attack and stroke are among the most serious threats to health. But novel research at University of Texas Southwestern Medical Center has linked two major biological processes that occur at the onset of these traumatic events and, ultimately, can lead to protection for the heart.
Mast Therapeutics Inc. announced that, in a placebo-controlled, nonclinical model of chronic heart failure, MST-188 demonstrated a statistically significant improvement in numerous parameters of heart function, including left ventricular ejection fraction and end-systolic volume, stroke volume and cardiac output.
Providing exceptional cardiovascular care for patients to achieve the best possible outcomes is the number one goal for ...
Taking their pick, biomedical researchers can now conduct five different imaging studies in one scan with a state-of-the-art preclinical molecular imaging system that scientists unveiled during the Society of Nuclear Medicine and Molecular Imaging’s 2014 Annual Meeting.
June 10, 2014 — Ariad Pharmaceuticals Inc. and Medinol Ltd. earlier this year initiated two registration trials of Medinol’s NIRsupreme ridaforolimus-eluting coronary stent system incorporating Ariad’s mTOR inhibitor, ridaforolimus. The two NIRsupreme trials are randomized, single-blind, global studies taking place in the United States, Europe, Israel and Canada and will enroll approximately 2,200 patients with coronary artery disease.

June 10, 2014 — A real-time monitoring device that beeps in the presence of high doses of radiation can help reduce patient and interventional cardiologist exposure to radiation during cardiac catheterization, according to results of the RadiCure study presented as a late-breaking clinical trial at the Society for Cardiovascular Angiography and Interventions (SCAI) 2014 scientific sessions in Las Vegas.
Cardiac positron emission tomography (PET) is growing in popularity among cardiologists because it provides the ability ...

June 9, 2014 — After one year, patients treated with orbital atherectomy, a procedure to sand away calcium in the coronary arteries prior to stenting, were less likely to require a repeat procedure to reopen their vessel or suffer a heart attack or death compared to other published trials in patients with heavily calcified arteries. The new results from the ORBIT II study were presented as a late-breaking clinical trial at the Society for Cardiovascular Angiography and Interventions (SCAI) 2014 scientific sessions in Las Vegas.
June 9, 2014 — Kalila Medical’s Vado steerable introducer sheath for vascular and intracardiac access, including atrial fibrillation (AF) procedures, has CE mark approval.
Researchers at the Society of Nuclear Medicine and Molecular Imaging’s 2014 Annual Meeting (SNMMI) revealed how a protein encourages the production of stem cells that regenerate damaged tissues of the heart following an acute attack (myocardial infarction). They further assert that it has a better chance of working if provided early in treatment. This was confirmed by molecular imaging, which captured patients’ improved heart health after therapy.
When performing radiofrequency (RF) ablation to treat cardiac arrhythmia, medical professionals must balance the safety ...
At the 2014 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), June 7-11, at the St. Louis Convention Center, Siemens Healthcare will debut syngo.via for molecular imaging — a reading solution that transforms large amounts of data into comprehensive results, allowing for organ-based reading [1], reference-based quantification [2] and evidence-based reporting [3] of disease.
At the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting, GE Healthcare introduced its Discovery* IQ^ PET/CT (positron emission tomography/ computed tomography) system enabling both outstanding image quality and intelligent quantitation, helping physicians to deliver the best possible patient outcomes.
Continuing to expand its portfolio of endovascular solutions, Medtronic Inc. announced that two recently U.S. Food and Drug Administration (FDA) approved devices will be featured at the Society for Vascular Surgery’s 2014 Vascular Annual Meeting, taking place June 5-7 in Boston.